Diagnosis and management of coronavirus disease-associated immune thrombocytopenia: a case series

Aydin, Fatma; Demircan, Vehbi

doi:10.1590/0037-8682-0029-2021

Cited by 6 publications

(3 citation statements)

References 12 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 6 case series with 35 patients were included in this study. One study was conducted in Turkey [ 24 ], one in Greece [ 25 ], one in the Netherlands [ 26 ], one in the USA [ 27 ], and one in France [ 28 ]. The participants’ ages ranged from a 3-year-old female patient who presented with a low-grade fever for one day, epistaxis, and melena and was diagnosed with ITP related to SARS- CoV-2 [ 25 ] to an 89-year-old male patient who presented with fever, cough, shortness of breath (SOB), and gastrointestinal (GI) symptoms and a preexisting medical history of hypertension, atrial fibrillation, DM, and chronic kidney disease (CKD) [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis

Alharbi

2022

Expert Review of Hematology

View full text Add to dashboard Cite

Background Immune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), has emerged as a significant COVID-19-associated complication. This study analyzes the published literature of case reports and case series regarding COVID-19 infection associated with ITP. Methodology In this systematic review and meta-analysis, a systematic search was conducted through PubMed, Web of Science, and Medline through Clarivate and EBSCO to include the eligible studies. The authors utilized Review Manager 5.4 to conduct quantitative data synthesis for the condition of interest analysis. Results A total of 13 eligible case reports and case series with 42 patients were included in this study; 54.8% of them were male. The pooled mean age of all participants was (59.5 ± 19) years with a median age of 63 years. The estimated mean time from diagnosis with COVID-19 to ITP development was 18.1 ± 21 days and the mean time to recovery from ITP was 5.8 ± 4.8 days. The pooled random effect of mean platelet count in the included six studies was 14.52, CI [8.79, 20.25]. Conclusion Our analysis shows that ITP secondary to COVID-19 infection is slightly more prevalent among males (54.8%). Elderly patients were more vulnerable to the disease. Most cases developed ITP within 2–3 weeks after COVID-19 infection and recovered in less than one week from ITP.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The patient was discharged with a stable medical state, given a vitamin K supplement and prednisone. Aydın et al, 2021 [ 24 ] NA Within 2–4 days IVIG was administered (1 g/kg). NA Within 2–4 days IVIG was administered (1 g/kg).…”

Section: Clinical Characteristics Of the Included Studiesmentioning

confidence: 99%

COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis

Alharbi

2022

Expert Review of Hematology

View full text Add to dashboard Cite

show abstract

“…Apart from the above, COVID-19 has been associated with de novo immune thrombocytopenia that may otherwise occur with various viral infections [ 92 , 93 ]. Again, mechanisms of pathogenesis and their interrelationship with other COVID-19-related platelet disorders remain to be defined.…”

Section: Heparin-induced Thrombocytopenia During Covid-19mentioning

confidence: 99%

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Advanced SARS-CoV-2 infections not uncommonly associate with the occurrence of silent or manifest thrombotic events which may be found as focal or systemic disease. Given the potential complexity of COVID-19 illnesses, a multifactorial causation is likely, but several studies have focused on infection-induced coagulopathy. Procoagulant states are commonly found in association with the finding of antiphospholipid antibodies. The correlation of the latter with thrombosis and/or clinical severity remains controversial. Although measures of antiphospholipid antibodies most commonly include assessments for lupus anticoagulant, anticardiolipin, and anti-ß2-glycoprotein-I antibodies, lesser common antibodies have been detected, and there remains speculation that other yet undiscovered autoimmune thrombotic events may yet be found. The recent discovery of post-vaccination thromboses associated with platelet factor 4 antibody has created another level of concern. The pathogenesis of antiphospholipid antibodies and their role in COVID-19-related thrombosis deserves further attention. The multifactorial nature of thrombosis associated with both infection and vaccination should continue to be studied as new events unfold. Even if a cause-and-effect relationship is variable at best, such dedicated research is likely to generate other valuable insights that are applicable to medicine generally.

show abstract

Autoimmune complications of COVID‐19

Yazdanpanah

Rezaei

2021

Journal of Medical Virology

108

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is still propagating a year after the start of the pandemic. Besides the complications patients face during the COVID-19 disease period, there is an accumulating body of evidence concerning the late-onset complications of COVID-19, of which autoimmune manifestations have attracted remarkable attention from the first months of the pandemic. Autoimmune hemolytic anemia, immune thrombocytopenic purpura, autoimmune thyroid diseases, Kawasaki disease, Guillain-Barre syndrome, and the detection of autoantibodies are the cues to the discovery of the potential of COVID-19 in inducing autoimmunity.Clarification of the pathophysiology of COVID-19 injuries to the host, whether it is direct viral injury or autoimmunity, could help to develop appropriate treatment.

show abstract

Diagnosis and management of coronavirus disease-associated immune thrombocytopenia: a case series

Cited by 6 publications

References 12 publications

COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis

COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19

Autoimmune complications of COVID‐19

Contact Info

Product

Resources

About